Choroideremia Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Choroideremia Overview

Choroideremia is a rare genetic disorder of vision that is more common in man. It is an X-linked recessive condition that leads to gradual degradation of choroid, retinal pigment epithelium (RPE), and photoreceptors. Female are mostly the carriers and mostly unaffected, even so they can experience minor symptoms, such as blurred vision in later stages of their life

“Choroideremia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Choroideremia Market.

The Choroideremia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Choroideremia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Choroideremia treatment therapies with a considerable amount of success over the years. Choroideremia Key players such as – Curative Biotech, 4D Molecular Therapeutics, Spark Therapeutics, NightstaRx Ltd., and others, are developing therapies for the Choroideremia treatment 

• Choroideremia Emerging therapies such as – Metformin, 4D-110, SPK-7001, BIIB111, and others are expected to have a significant impact on the Choroideremia market in the coming years.   
• In June 2021, NightstaRx Ltd announced that the results from Phase III did not satisfy the primary endpoint and secondary efficacy endpoints. Therefore, they will evaluate the results before confirming the next step of the study
• In November 2018, NightstaRx Ltd. initiated the Phase II trial, to evaluate the safety of bilateral, sequential subretinal administration of a single dose of BIIB111 in adult male participants with Choroideremia

Route of Administration

Choroideremia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Choroideremia Pipeline Therapeutics Assessment

• Choroideremia Assessment by Product Type
• Choroideremia By Stage and Product Type
• Choroideremia Assessment by Route of Administration
• Choroideremia By Stage and Route of Administration
• Choroideremia Assessment by Molecule Type
• Choroideremia by Stage and Molecule Type

DelveInsight’s Choroideremia Report covers around 5+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Choroideremia Therapeutics Market include:

Key companies developing therapies for Choroideremia are – NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others.

Emerging Choroideremia Drugs Under Different Phases of Clinical Development Include:

• Metformin: Curative Biotech
• 4D-110: 4D Molecular Therapeutics
• SPK-7001: Spark Therapeutics
• BIIB111: NightstaRx Ltd.

Get a Free Sample PDF Report to know more about Choroideremia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/choroideremia-pipeline-insight

Choroideremia Pipeline Analysis:

The Choroideremia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Choroideremia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Choroideremia Treatment.
• Choroideremia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Choroideremia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Choroideremia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Choroideremia product details are provided in the report. Download the Choroideremia pipeline report to learn more about the emerging Choroideremia therapies

Scope of Choroideremia Pipeline Drug Insight    

• Coverage: Global
• Key Choroideremia Companies: Curative Biotech, 4D Molecular Therapeutics, Spark Therapeutics, NightstaRx Ltd., and others
• Key Choroideremia Therapies: Metformin, 4D-110, SPK-7001, BIIB111, and others
• Choroideremia Therapeutic Assessment: Choroideremia current marketed and Choroideremia emerging therapies
• Choroideremia Market Dynamics: Choroideremia market drivers and Choroideremia market barriers 

Request for Sample PDF Report for Choroideremia Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Choroideremia drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis